APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live and Attenuated Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Live and Attenuated Vaccine Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchLive and Attenuated Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Live and Attenuated Vaccine Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Live and Attenuated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live and Attenuated Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Live and Attenuated Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Live and Attenuated Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Live and Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live and Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live and Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Live and Attenuated Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Live and Attenuated Vaccine market include Sanofi, Johnson & Johnson, Merck & Co., Pfizer, Inc, GlaxoSmithKline, Serum Institute, MedImmune, LLC, Emergent BioSolutions, Inc. and CSL Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Live and Attenuated Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live and Attenuated Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live and Attenuated Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Live and Attenuated Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Live and Attenuated Vaccine Segment by Company

Sanofi

Johnson & Johnson

Merck & Co.

Pfizer, Inc

GlaxoSmithKline

Serum Institute

MedImmune, LLC

Emergent BioSolutions, Inc.

CSL Limited

Astellas Pharma Inc

Live and Attenuated Vaccine Segment by Type

Pediatric Vaccine

Adult Vaccines

Live and Attenuated Vaccine Segment by Application

Clinics

Diagnostic Centers

Hospitals

Research Institute

Others

Live and Attenuated Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Live and Attenuated Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Live and Attenuated Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Live and Attenuated Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Live and Attenuated Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live and Attenuated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live and Attenuated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live and Attenuated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live and Attenuated Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Live and Attenuated Vaccine industry.

Chapter 3: Detailed analysis of Live and Attenuated Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Live and Attenuated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Live and Attenuated Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Live and Attenuated Vaccine Industry Trends Table 2. Live and Attenuated Vaccine Industry Drivers Table 3. Live and Attenuated Vaccine Industry Opportunities and Challenges Table 4. Live and Attenuated Vaccine Industry Restraints Table 5. Global Live and Attenuated Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Live and Attenuated Vaccine Revenue Share by Company (2021-2026) Table 7. Global Live and Attenuated Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Live and Attenuated Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Live and Attenuated Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Live and Attenuated Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Live and Attenuated Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Live and Attenuated Vaccine Company, Product Type & Application Table 13. Global Live and Attenuated Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Live and Attenuated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Pediatric Vaccine Table 18. Significant Companies of Adult Vaccines Table 19. Global Live and Attenuated Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Live and Attenuated Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Live and Attenuated Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Live and Attenuated Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Live and Attenuated Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Live and Attenuated Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Live and Attenuated Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Live and Attenuated Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Live and Attenuated Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Live and Attenuated Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Clinics Table 30. Significant Companies of Diagnostic Centers Table 31. Significant Companies of Hospitals Table 32. Significant Companies of Research Institute Table 33. Significant Companies of Others Table 34. Global Live and Attenuated Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Live and Attenuated Vaccine Sales Volume by Application (2021-2026) & (k units) Table 36. Global Live and Attenuated Vaccine Sales Volume by Application (2027-2032) & (k units) Table 37. Global Live and Attenuated Vaccine Sales Volume Share by Application (2021-2026) Table 38. Global Live and Attenuated Vaccine Sales Volume Share by Application (2027-2032) Table 39. Global Live and Attenuated Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Live and Attenuated Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Live and Attenuated Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Live and Attenuated Vaccine Sales Value Share by Application (2021-2026) Table 43. Global Live and Attenuated Vaccine Sales Value Share by Application (2027-2032) Table 44. Global Live and Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Live and Attenuated Vaccine Sales by Region (2021-2026) & (k units) Table 46. Global Live and Attenuated Vaccine Sales Market Share by Region (2021-2026) Table 47. Global Live and Attenuated Vaccine Sales by Region (2027-2032) & (k units) Table 48. Global Live and Attenuated Vaccine Sales Market Share by Region (2027-2032) Table 49. Global Live and Attenuated Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Live and Attenuated Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Live and Attenuated Vaccine Sales Value Share by Region (2021-2026) Table 52. Global Live and Attenuated Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Live and Attenuated Vaccine Sales Value Share by Region (2027-2032) Table 54. Global Live and Attenuated Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Live and Attenuated Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Live and Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Live and Attenuated Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 59. Global Live and Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 60. Global Live and Attenuated Vaccine Sales by Country (2027-2032) & (k units) Table 61. Global Live and Attenuated Vaccine Sales Market Share by Country (2027-2032) Table 62. Global Live and Attenuated Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Live and Attenuated Vaccine Sales Value Market Share by Country (2021-2026) Table 64. Global Live and Attenuated Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Live and Attenuated Vaccine Sales Value Market Share by Country (2027-2032) Table 66. Sanofi Company Information Table 67. Sanofi Business Overview Table 68. Sanofi Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Sanofi Live and Attenuated Vaccine Product Portfolio Table 70. Sanofi Recent Development Table 71. Johnson & Johnson Company Information Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Johnson & Johnson Live and Attenuated Vaccine Product Portfolio Table 75. Johnson & Johnson Recent Development Table 76. Merck & Co. Company Information Table 77. Merck & Co. Business Overview Table 78. Merck & Co. Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Merck & Co. Live and Attenuated Vaccine Product Portfolio Table 80. Merck & Co. Recent Development Table 81. Pfizer, Inc Company Information Table 82. Pfizer, Inc Business Overview Table 83. Pfizer, Inc Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Pfizer, Inc Live and Attenuated Vaccine Product Portfolio Table 85. Pfizer, Inc Recent Development Table 86. GlaxoSmithKline Company Information Table 87. GlaxoSmithKline Business Overview Table 88. GlaxoSmithKline Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. GlaxoSmithKline Live and Attenuated Vaccine Product Portfolio Table 90. GlaxoSmithKline Recent Development Table 91. Serum Institute Company Information Table 92. Serum Institute Business Overview Table 93. Serum Institute Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Serum Institute Live and Attenuated Vaccine Product Portfolio Table 95. Serum Institute Recent Development Table 96. MedImmune, LLC Company Information Table 97. MedImmune, LLC Business Overview Table 98. MedImmune, LLC Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. MedImmune, LLC Live and Attenuated Vaccine Product Portfolio Table 100. MedImmune, LLC Recent Development Table 101. Emergent BioSolutions, Inc. Company Information Table 102. Emergent BioSolutions, Inc. Business Overview Table 103. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolio Table 105. Emergent BioSolutions, Inc. Recent Development Table 106. CSL Limited Company Information Table 107. CSL Limited Business Overview Table 108. CSL Limited Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. CSL Limited Live and Attenuated Vaccine Product Portfolio Table 110. CSL Limited Recent Development Table 111. Astellas Pharma Inc Company Information Table 112. Astellas Pharma Inc Business Overview Table 113. Astellas Pharma Inc Live and Attenuated Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolio Table 115. Astellas Pharma Inc Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. Live and Attenuated Vaccine Distributors List Table 119. Live and Attenuated Vaccine Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Live and Attenuated Vaccine Product Image Figure 2. Global Live and Attenuated Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live and Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Live and Attenuated Vaccine Sales (2021-2032) & (k units) Figure 5. Global Live and Attenuated Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Live and Attenuated Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Pediatric Vaccine Image Figure 10. Adult Vaccines Image Figure 11. Global Live and Attenuated Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Live and Attenuated Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Live and Attenuated Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Live and Attenuated Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Live and Attenuated Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Live and Attenuated Vaccine Sales Value Share by Type (2021-2032) Figure 17. Clinics Image Figure 18. Diagnostic Centers Image Figure 19. Hospitals Image Figure 20. Research Institute Image Figure 21. Others Image Figure 22. Global Live and Attenuated Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Live and Attenuated Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Live and Attenuated Vaccine Sales Volume Share by Application (2021-2032) Figure 25. Global Live and Attenuated Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Live and Attenuated Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Live and Attenuated Vaccine Sales Value Share by Application (2021-2032) Figure 28. Global Live and Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Live and Attenuated Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Live and Attenuated Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Live and Attenuated Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Live and Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. North America Live and Attenuated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Live and Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Live and Attenuated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Live and Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Live and Attenuated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Live and Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. South America Live and Attenuated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Live and Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Live and Attenuated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Live and Attenuated Vaccine Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Live and Attenuated Vaccine Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Pediatric Vaccine
  • Adult Vaccines
Applications
  • Clinics
  • Diagnostic Centers
  • Hospitals
  • Research Institute
  • Others
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer, Inc
  • GlaxoSmithKline
  • Serum Institute
  • MedImmune, LLC
  • Emergent BioSolutions, Inc.
  • CSL Limited
  • Astellas Pharma Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Live and Attenuated Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Live and Attenuated Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Live and Attenuated Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Live and Attenuated Vaccine Market Dynamics
  1. 2.1 Live and Attenuated Vaccine Industry Trends
  2. 2.2 Live and Attenuated Vaccine Industry Drivers
  3. 2.3 Live and Attenuated Vaccine Industry Opportunities and Challenges
  4. 2.4 Live and Attenuated Vaccine Industry Restraints
3 Live and Attenuated Vaccine Market by Company
  1. 3.1 Global Live and Attenuated Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Live and Attenuated Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Live and Attenuated Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Live and Attenuated Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Live and Attenuated Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Live and Attenuated Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Live and Attenuated Vaccine Company Product Type and Application
  8. 3.8 Global Live and Attenuated Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Live and Attenuated Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Live and Attenuated Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Live and Attenuated Vaccine Market by Type
  1. 4.1 Live and Attenuated Vaccine Type Introduction
  2. 4.1.1 Pediatric Vaccine
  3. 4.1.2 Adult Vaccines
  4. 4.2 Global Live and Attenuated Vaccine Sales Volume by Type
  5. 4.2.1 Global Live and Attenuated Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Live and Attenuated Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Live and Attenuated Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Live and Attenuated Vaccine Sales Value by Type
  9. 4.3.1 Global Live and Attenuated Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Live and Attenuated Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Live and Attenuated Vaccine Sales Value Share by Type (2021-2032)
5 Live and Attenuated Vaccine Market by Application
  1. 5.1 Live and Attenuated Vaccine Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Diagnostic Centers
  4. 5.1.3 Hospitals
  5. 5.1.4 Research Institute
  6. 5.1.5 Others
  7. 5.2 Global Live and Attenuated Vaccine Sales Volume by Application
  8. 5.2.1 Global Live and Attenuated Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Live and Attenuated Vaccine Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Live and Attenuated Vaccine Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Live and Attenuated Vaccine Sales Value by Application
  12. 5.3.1 Global Live and Attenuated Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Live and Attenuated Vaccine Sales Value by Application (2021-2032)
  14. 5.3.3 Global Live and Attenuated Vaccine Sales Value Share by Application (2021-2032)
6 Live and Attenuated Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Live and Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Live and Attenuated Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Live and Attenuated Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Live and Attenuated Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Live and Attenuated Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Live and Attenuated Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Live and Attenuated Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Live and Attenuated Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Live and Attenuated Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Live and Attenuated Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Live and Attenuated Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Live and Attenuated Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Live and Attenuated Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Live and Attenuated Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Live and Attenuated Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Live and Attenuated Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Live and Attenuated Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Live and Attenuated Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Live and Attenuated Vaccine Sales Value Share by Country, 2025 VS 2032
7 Live and Attenuated Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Live and Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Live and Attenuated Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Live and Attenuated Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Live and Attenuated Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Live and Attenuated Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Live and Attenuated Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Live and Attenuated Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Live and Attenuated Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Live and Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Live and Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Live and Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Live and Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Live and Attenuated Vaccine Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Live and Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Live and Attenuated Vaccine Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Merck & Co.
  14. 8.3.1 Merck & Co. Company Information
  15. 8.3.2 Merck & Co. Business Overview
  16. 8.3.3 Merck & Co. Live and Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co. Live and Attenuated Vaccine Product Portfolio
  18. 8.3.5 Merck & Co. Recent Developments
  19. 8.4 Pfizer, Inc
  20. 8.4.1 Pfizer, Inc Company Information
  21. 8.4.2 Pfizer, Inc Business Overview
  22. 8.4.3 Pfizer, Inc Live and Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer, Inc Live and Attenuated Vaccine Product Portfolio
  24. 8.4.5 Pfizer, Inc Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Live and Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Live and Attenuated Vaccine Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 Serum Institute
  32. 8.6.1 Serum Institute Company Information
  33. 8.6.2 Serum Institute Business Overview
  34. 8.6.3 Serum Institute Live and Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Serum Institute Live and Attenuated Vaccine Product Portfolio
  36. 8.6.5 Serum Institute Recent Developments
  37. 8.7 MedImmune, LLC
  38. 8.7.1 MedImmune, LLC Company Information
  39. 8.7.2 MedImmune, LLC Business Overview
  40. 8.7.3 MedImmune, LLC Live and Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 MedImmune, LLC Live and Attenuated Vaccine Product Portfolio
  42. 8.7.5 MedImmune, LLC Recent Developments
  43. 8.8 Emergent BioSolutions, Inc.
  44. 8.8.1 Emergent BioSolutions, Inc. Company Information
  45. 8.8.2 Emergent BioSolutions, Inc. Business Overview
  46. 8.8.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolio
  48. 8.8.5 Emergent BioSolutions, Inc. Recent Developments
  49. 8.9 CSL Limited
  50. 8.9.1 CSL Limited Company Information
  51. 8.9.2 CSL Limited Business Overview
  52. 8.9.3 CSL Limited Live and Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 CSL Limited Live and Attenuated Vaccine Product Portfolio
  54. 8.9.5 CSL Limited Recent Developments
  55. 8.10 Astellas Pharma Inc
  56. 8.10.1 Astellas Pharma Inc Company Information
  57. 8.10.2 Astellas Pharma Inc Business Overview
  58. 8.10.3 Astellas Pharma Inc Live and Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolio
  60. 8.10.5 Astellas Pharma Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Live and Attenuated Vaccine Value Chain Analysis
  2. 9.1.1 Live and Attenuated Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Live and Attenuated Vaccine Sales Mode & Process
  6. 9.2 Live and Attenuated Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Live and Attenuated Vaccine Distributors
  9. 9.2.3 Live and Attenuated Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst